# OnCo record nct05501886 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05501886/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05501886", "NCT05501886" ;
  schema:name "Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)"@en ;
  schema:alternateName "VIKTORIA-1"@en ;
  schema:description "A phase 3 trial of Gedatolisib, Palbociclib, Fulvestrant and Alpelisib in advanced solid tumours, run by Celcuity Inc, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05501886/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05501886> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2022-12-08" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:technologies <https://onco.cc/technologies/cdk46-inhibitor/>, <https://onco.cc/technologies/endocrine-therapy/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/gedatolisib/>, <https://onco.cc/drugs/palbociclib/>, <https://onco.cc/drugs/fulvestrant/>, <https://onco.cc/drugs/alpelisib/> ;
  onco:companies <https://onco.cc/companies/celcuity/> .